skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Belagenpumatucel-L (Code C73438)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Belagenpumatucel-L

Definition: A transforming growth factor beta2 (TGF-beta2) antisense gene-modified allogeneic tumor cell vaccine with potential immunostimulatory and antineoplastic activities. Belagenpumatucel-L is prepared by transfecting allogeneic non-small cell lung cancer (NSCLC) cells with a plasmid containing a TGF-beta2 antisense transgene, expanding the cells, and then irradiating and freezing them. Upon administration, this agent may elicit a cytotoxic T lymphocyte (CTL) response against host NSCLC cells, resulting in decreased tumor cell proliferation; vaccine immunogenicity may be potentiated by suppression of tumor TGF-beta2 production by antisense RNA expressed by the vaccine plasmid TGF-beta2 antisense transgene. Elevated levels of TGF-beta2 are frequently linked to immunosuppression in cancer patients and may be inversely correlated with prognosis in patients with NSCLC.

Display Name: Belagenpumatucel-L

Label: Belagenpumatucel-L

NCI Thesaurus Code: C73438 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C1739687  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)

External Source Codes: 
PDQ Closed Trial Search ID 590662
PDQ Open Trial Search ID 590662 (check for NCI PDQ open clinical trial info)
UMLS CUI C1739687

Other Properties:
     Name Value (qualifiers indented underneath)
code C73438
Contributing_Source CTRP
Legacy_Concept_Name Belagenpumatucel-L
Semantic_Type Cell
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom